Amdocs Limited (NASDAQ:DOX – Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 2,810,000 shares, an increase of 5.2% from the August 31st total of 2,670,000 shares. Approximately 2.5% of the company’s shares are short sold. Based on an average daily trading volume, of 653,400 shares, the short-interest ratio is currently 4.3 days.
Wall Street Analyst Weigh In
Separately, StockNews.com raised Amdocs from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 13th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Amdocs presently has an average rating of “Buy” and a consensus price target of $102.50.
Read Our Latest Analysis on DOX
Amdocs Stock Down 0.1 %
Amdocs (NASDAQ:DOX – Get Free Report) last posted its earnings results on Wednesday, August 7th. The technology company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.02. The firm had revenue of $1.25 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Amdocs had a return on equity of 17.89% and a net margin of 10.21%. The business’s revenue was up 1.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.41 earnings per share. Sell-side analysts forecast that Amdocs will post 5.67 earnings per share for the current year.
Amdocs Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be issued a $0.479 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $1.92 annualized dividend and a yield of 2.19%. Amdocs’s dividend payout ratio (DPR) is presently 42.92%.
Hedge Funds Weigh In On Amdocs
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Norwood Financial Corp bought a new position in Amdocs in the first quarter worth $33,000. Central Pacific Bank Trust Division purchased a new stake in shares of Amdocs in the 1st quarter worth about $53,000. Riverview Trust Co purchased a new stake in shares of Amdocs in the 1st quarter worth about $55,000. Quarry LP increased its stake in shares of Amdocs by 168.9% in the 4th quarter. Quarry LP now owns 656 shares of the technology company’s stock worth $58,000 after acquiring an additional 412 shares in the last quarter. Finally, American National Bank purchased a new position in Amdocs during the 2nd quarter valued at about $76,000. Hedge funds and other institutional investors own 92.02% of the company’s stock.
About Amdocs
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
Recommended Stories
- Five stocks we like better than Amdocs
- Retail Stocks Investing, Explained
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 5 Top Rated Dividend Stocks to Consider
- 2 Energy Stocks Fueling the AI Datacenter Boom
- 3 Tickers Leading a Meme Stock Revival
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Amdocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amdocs and related companies with MarketBeat.com's FREE daily email newsletter.